JP2015508181A - 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 - Google Patents

腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 Download PDF

Info

Publication number
JP2015508181A
JP2015508181A JP2014558960A JP2014558960A JP2015508181A JP 2015508181 A JP2015508181 A JP 2015508181A JP 2014558960 A JP2014558960 A JP 2014558960A JP 2014558960 A JP2014558960 A JP 2014558960A JP 2015508181 A JP2015508181 A JP 2015508181A
Authority
JP
Japan
Prior art keywords
hours
subject
future
assigning
serum creatinine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508181A5 (enExample
Inventor
アンダーバーグ，ジョセフ
グレイ，ジェフ
マクファーソン，ポール
ナカムラ，ケビン
カンプフ，ジェイムズ，パトリック
Original Assignee
アスチュート メディカル，インコーポレイテッド
アスチュート メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アスチュート メディカル，インコーポレイテッド, アスチュート メディカル，インコーポレイテッド filed Critical アスチュート メディカル，インコーポレイテッド
Publication of JP2015508181A publication Critical patent/JP2015508181A/ja
Publication of JP2015508181A5 publication Critical patent/JP2015508181A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1601—Control or regulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/75—General characteristics of the apparatus with filters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2014558960A 2012-02-27 2013-02-27 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 Pending JP2015508181A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261603912P 2012-02-27 2012-02-27
US201261603906P 2012-02-27 2012-02-27
US61/603,906 2012-02-27
US61/603,912 2012-02-27
PCT/US2013/028000 WO2013130591A1 (en) 2012-02-27 2013-02-27 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
JP2015508181A true JP2015508181A (ja) 2015-03-16
JP2015508181A5 JP2015508181A5 (enExample) 2016-03-17

Family

ID=49083233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558960A Pending JP2015508181A (ja) 2012-02-27 2013-02-27 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Country Status (9)

Country Link
US (1) US20150010929A1 (enExample)
EP (1) EP2820146A4 (enExample)
JP (1) JP2015508181A (enExample)
CN (1) CN104379758A (enExample)
AU (1) AU2013226181A1 (enExample)
CA (1) CA2865559A1 (enExample)
HK (1) HK1204339A1 (enExample)
IN (1) IN2014MN01759A (enExample)
WO (1) WO2013130591A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013113018A1 (en) * 2012-01-28 2013-08-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
AU2016275071A1 (en) * 2015-06-11 2018-02-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075016A1 (en) * 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2010048346A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US20090178145A1 (en) * 2005-05-11 2009-07-09 The Procter & Gamble Company Methods and targets for identifying compounds for regulating angiogenesis
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation
CA2751435A1 (en) * 2009-02-06 2010-08-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and failure
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075016A1 (en) * 2002-03-07 2003-09-12 Cambridge University Technical Services Limited (Cuts) Scd fingerprints
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
WO2010048346A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010128158A1 (en) * 2009-05-08 2010-11-11 Novartis Ag Diagnostic biomarkers for fibrotic disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADAMS, D.C. ET AL.: "Follistatin-Like 1 Regulates Renal IL-lBeta Expression In Cisplatin Nephrotoxicity", AM. J. PHYSIOL. RENAL PHYSIOL., vol. 299, no. 6, JPN6016044972, 29 September 2010 (2010-09-29), pages 1320 - 1327, XP055163044, ISSN: 0003445795 *
MOVVA SIREESHA ET AL.: ""Relevance of insulin-like growth factor 2 in the etiopathophysiology of diabetic nephropathy: Possi", JOURNAL OF DIABETES, vol. 1, no. 2, JPN6016044971, 26 June 2009 (2009-06-26), pages 118 - 124, XP055202553, ISSN: 0003445794, DOI: 10.1111/j.1753-0407.2009.00025.x *

Also Published As

Publication number Publication date
EP2820146A1 (en) 2015-01-07
EP2820146A4 (en) 2015-12-16
AU2013226181A1 (en) 2014-09-18
CN104379758A (zh) 2015-02-25
WO2013130591A1 (en) 2013-09-06
US20150010929A1 (en) 2015-01-08
IN2014MN01759A (enExample) 2015-07-03
HK1204339A1 (en) 2015-11-13
CA2865559A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
JP6363154B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6681195B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6054481B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6609533B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2017032586A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP5981144B2 (ja) 腎損傷および腎不全の診断および予後診断
JP6321080B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP5827226B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2012517594A (ja) 腎損傷および腎不全の診断および予後診断のための方法および組成物
KR102431003B1 (ko) 신손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
JP6185035B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016194526A (ja) 腎損傷および腎不全の診断および予後診断のための方法および組成物
JP6403712B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016136154A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6186400B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2014521088A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2015508181A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP6538353B2 (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2015524926A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2016505860A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2018518676A (ja) 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170704